UBS lowered the firm’s price target on Pfizer (PFE) to $29 from $31 and keeps a Neutral rating on the shares as part of a broader note on the ...

Range Financial Group LLC purchased a new stake in Pfizer Inc. (NYSE:PFE – Free Report) during the fourth quarter, according ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Pfizer (PFE – Research Report), with a ...

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced an ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Lumotive, a pioneer in optical semiconductor technology, today announced the integration of its groundbreaking MD41 Development Kit with Sony Semiconductor Solutions' IMX459 and ...

Oliver Luxxe Assets LLC lifted its position in Pfizer Inc. (NYSE:PFE – Free Report) by 2.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange ...

Pfizer Inc. closed $4.65 short of its 52-week high ($31.54), which the company reached on July 30th.

Mexico's tax authority SAT issued new tariffs on Tuesday, which it said will strengthen the surveillance of goods from Asia, ...

"Federal law requires defendants to ensure that their drug labels remain accurate, and when new scientific information ...

The stock's fall snapped a three-day winning streak.